Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Microsoft
MSFT
|
+$7.54B |
| 2 |
Apple
AAPL
|
+$5.11B |
| 3 |
Amazon
AMZN
|
+$2.93B |
| 4 |
UnitedHealth
UNH
|
+$2.83B |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$2.75B |
Top Sells
| 1 |
ZEN
ZENDESK INC
ZEN
|
+$330M |
| 2 |
Snap
SNAP
|
+$321M |
| 3 |
Twilio
TWLO
|
+$309M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$156M |
| 5 |
AVLR
Avalara, Inc.
AVLR
|
+$154M |
Sector Composition
| 1 | Technology | 29.71% |
| 2 | Healthcare | 21.23% |
| 3 | Financials | 11.2% |
| 4 | Consumer Discretionary | 10.46% |
| 5 | Industrials | 9.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2351
Theravance Biopharma
TBPH
$701M
| $224K | ﹤0.01% |
21,978
+10,904
| +98% | +$111K |
|
|
EVBG
2352
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $224K | ﹤0.01% |
7,226
+17
| +0.2% | +$527 |
|
2353
Axsome Therapeutics
AXSM
$6.45B
| $222K | ﹤0.01% |
+4,968
| New | +$222K |
|
|
RDFN
2354
DELISTED
Redfin
RDFN
| $222K | ﹤0.01% |
37,880
-3,709,891
| -99% | -$21.7M |
|
|
BRG
2355
DELISTED
Bluerock Residential Growth REIT, Inc.
BRG
| $221K | ﹤0.01% |
+8,249
| New | +$221K |
|
2356
Relmada Therapeutics
RLMD
$53.1M
| $220K | ﹤0.01% |
+5,937
| New | +$220K |
|
2357
TriMas Corp
TRS
$1.59B
| $220K | ﹤0.01% |
8,764
+15
| +0.2% | +$377 |
|
2358
Vanda Pharmaceuticals
VNDA
$269M
| $220K | ﹤0.01% |
22,292
+11,162
| +100% | +$110K |
|
|
MODN
2359
DELISTED
MODEL N, INC.
MODN
| $220K | ﹤0.01% |
+6,430
| New | +$220K |
|
|
MNRL
2360
DELISTED
Brigham Minerals, Inc. Class A Common Stock
MNRL
| $219K | ﹤0.01% |
8,896
+34
| +0.4% | +$837 |
|
|
BRSP
2361
BrightSpire Capital
BRSP
$772M
| $218K | ﹤0.01% |
34,448
+17,054
| +98% | +$108K |
|
2362
Clover Health Investments
CLOV
$1.4B
| $218K | ﹤0.01% |
127,682
+63,752
| +100% | +$109K |
|
2363
OneSpaWorld
OSW
$2.27B
| $218K | ﹤0.01% |
25,952
+12,976
| +100% | +$109K |
|
2364
Sphere Entertainment
SPHR
$1.96B
| $218K | ﹤0.01% |
4,967
+8
| +0.2% | +$351 |
|
2365
Tompkins Financial
TMP
$1.01B
| $218K | ﹤0.01% |
3,010
-14
| -0.5% | -$1.01K |
|
2366
Amphastar Pharmaceuticals
AMPH
$1.36B
| $217K | ﹤0.01% |
7,715
-52
| -0.7% | -$1.46K |
|
2367
QuinStreet
QNST
$936M
| $216K | ﹤0.01% |
20,580
+10,294
| +100% | +$108K |
|
2368
WisdomTree
WT
$2B
| $216K | ﹤0.01% |
45,824
+22,846
| +99% | +$108K |
|
2369
First Bancorp
FBNC
$2.3B
| $214K | ﹤0.01% |
5,846
+12
| +0.2% | +$439 |
|
2370
Heidrick & Struggles
HSII
$1.04B
| $214K | ﹤0.01% |
8,229
-164
| -2% | -$4.27K |
|
2371
Interface
TILE
$1.64B
| $214K | ﹤0.01% |
23,834
+11,937
| +100% | +$107K |
|
2372
ATAI Life Sciences
ATAI
$969M
| $212K | ﹤0.01% |
63,878
+31,939
| +100% | +$106K |
|
2373
Avanos Medical
AVNS
$577M
| $212K | ﹤0.01% |
9,736
+17
| +0.2% | +$370 |
|
|
BBBY
2374
Bed Bath & Beyond, Inc.
BBBY
$595M
| $212K | ﹤0.01% |
8,687
+17
| +0.2% | +$415 |
|
2375
Enova International
ENVA
$2.96B
| $212K | ﹤0.01% |
7,235
+3
| +0% | +$88 |
|